theliatinib
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT02601248)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C#Cc1cccc(Nc2ncnc3cc(OC)c(NC(=O)N4C[C@H]5CCN(C)[C@H]5C4)cc23)c1- Mol. weight
- 442.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314410 ↗
- ChEMBLCHEMBL3545180 ↗
Also known as
- hmpl-309
- theliatinib
- theliatinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02601274 | Phase 1 | Apr 1, 2015 | Hutchison MediPharma |
| NCT02601248 | Phase 1 | Oct 1, 2012 | Hutchison MediPharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hutchison MediPharma | For profit | 2 | 2 | 1 | 2012 |
1 organizations
Page 1 / 1